Genetics of drug response to immunosuppressive treatment and prospects for personalized therapy.
The use of immunosuppressive agents in the treatment of transplant rejection and autoimmune disorders is gaining momentum, with significant improvements of both graft and patient survival. The individual response to drugs, however, is variable and unexpected toxicity, or impaired activity might be seen, as a result of molecular determinants that eventually dictate how the individual will respond to immunosuppressive agents. This review addresses a number of issues related to pharmacogenetics, and discusses how this approach might be used to improve the clinical efficacy and tolerability of therapeutic options for the management of organ transplantation and autoimmune disorders in the next decade.
Danesi
R
R
Department of Oncology, Transplants and Advanced Technologies in Medicine, University of Pisa, 55 Via Roma, 56126 Pisa, Italy. r.danesi@med.unipi.it
Mosca
M
M
Boggi
U
U
Mosca
F
F
Del Tacca
M
M
D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000235:genetics; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016377:Organ Transplantation / Q000009:adverse effects; D010597:Pharmacogenetics
D007166:Immunosuppressive Agents